All tests for years with conventional treatments, to improve the rate of relapse, ended in failure. A totally new approach to treatment is a therapeutic vaccine that would prevent recurrence after initial successful treatment. The principle of this immunotherapeutic approach based on injection of a molecule called Abagovomab patients suffering from ovarian cancer. The vaccine stimulates the immune system of women so that it selects and destroy tumor cells to prevent tumor recurrence. Focus on principle rather conventional Vaccine:

• This molecule is an antigen designed to resemble the antigen CA125, a protein found in large quantities on the surface of tumor cells in ovarian cancer. The Abagovomab is nevertheless sufficiently different from the CA 125 in order to induce, once injected, the immune response of the patient against him, and thereby against the CA125 antigen, very close.
• A classic immune response occurs when: the antibodies induced by the patient specifically recognize antigens CA125 in the tumor cells and bind to, leading, ideally, the elimination of tumor cells carrying the antigen, now recognized as foreign. If the system works in practice is therefore the patient herself who synthesizes antibodies eradicating the tumor. Thanks to the vaccine based Abagovomab, the immune system should be able to recognize and attack tumor cells that have the protein CA125.

This could bring hope that the immune system starts to fight all residual tumor cells and that they succeed and to prevent any recurrence of the disease. “The medical community has great hopes on immunotherapy. She hopes that it will, finally, a treatment that will prevent recurrence often fatal cancer of the ovary.

If you needed another reason to drink green tea, here’s one: Japanese women who regularly drink five or more cups a day are 20 percent less likely to have stomach cancer.

A team of researchers studied the use of green tea for cancer prevention because he suspected that antioxidants protect the infusion of the fatal disease, especially because it would include substances that attack bacteria associated with stomach tumors.

But previous studies did not obtain conclusive results, they wrote in the journal Gut. To better understand the real effects of green tea, Dr. M. Inoue, National Cancer Center in Tokyo, and colleagues reviewed six of those previous works.

Together, the research included more than 219,000 men and women 40 years and older, who were followed over seven to 11 years. Four out of five respondents said they drank green tea daily; third drank five or more cups per day.

During follow up, about 2,500 of the nearly 100,000 men and about 1,000 of the over 118,000 women participants developed stomach cancer.

The researchers found no association among men between the highest tea consumption and lower cancer risk.

The 20 per cent reduction in risk of stomach cancer observed among women who drank five cups or more, over a cup or less of green tea per day, remained after taking account of smoking.

But the risk reduction was applied to tumors that arise in certain parts of the stomach.

The study does not prove a cause-effect, but suggests that more studies are needed to confirm whether drinking green tea reduces the risk of developing stomach cancer or whether women with lower risk of autism are those that consume more tea.

Incoming search terms for the article: